| __timestamp | Alpine Immune Sciences, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 59644696 |
| Thursday, January 1, 2015 | 6844000 | 79541000 |
| Friday, January 1, 2016 | 8586000 | 98015000 |
| Sunday, January 1, 2017 | 6079000 | 103958000 |
| Monday, January 1, 2018 | 8362000 | 103654000 |
| Tuesday, January 1, 2019 | 9467000 | 128951000 |
| Wednesday, January 1, 2020 | 10899000 | 135799000 |
| Friday, January 1, 2021 | 14560000 | 149883000 |
| Saturday, January 1, 2022 | 17968000 | 220206000 |
| Sunday, January 1, 2023 | 22222000 | 265542000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Alpine Immune Sciences, Inc. and Travere Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Alpine Immune Sciences saw a nearly tenfold increase in SG&A expenses, starting from a modest $2.3 million to $22.2 million. Meanwhile, Travere Therapeutics experienced a more than fourfold rise, from $59.6 million to $265.5 million.
Despite Travere's higher absolute expenses, their growth rate in SG&A costs was slower compared to Alpine's. This suggests a more controlled expansion strategy. Investors and industry analysts should consider these trends when evaluating the operational efficiency and strategic direction of these companies. Understanding how each company manages its SG&A expenses can provide insights into their long-term sustainability and market positioning.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Alpine Immune Sciences, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.